Germacranolides from Enhydra fluctuans with TRAIL-resistance abrogating activity

Firoj Ahmed, Utpal K. Karmakar, Midori A. Arai, Naoki Ishikawa, Samir K. Sadhu, Masami Ishibashi

Research output: Contribution to journalArticle


TRAIL selectively kills cancer cells without harming most normal cells. However, TRAIL resistance is a major problem for its therapeutic use. Developing a strategy to overcome resistance is crucial for the successful use of TRAIL as an antitumor agent. In our screening program of natural products that can abrogate TRAIL resistance, four germacranolides (1-4) were isolated from the aerial parts of Enhydra fluctuans. All compounds exhibited potent TRAILresistance overcoming activity against TRAIL-resistant human gastric adenocarcinoma (AGS) cells.

Original languageEnglish
Pages (from-to)1169-1170
Number of pages2
JournalNatural product communications
Issue number8
Publication statusPublished - 2017 Jan 1
Externally publishedYes


  • Enhydra fluctuans
  • TRAIL-resistance overcoming activity

ASJC Scopus subject areas

  • Pharmacology
  • Plant Science
  • Drug Discovery
  • Complementary and alternative medicine

Fingerprint Dive into the research topics of 'Germacranolides from Enhydra fluctuans with TRAIL-resistance abrogating activity'. Together they form a unique fingerprint.

  • Cite this

    Ahmed, F., Karmakar, U. K., Arai, M. A., Ishikawa, N., Sadhu, S. K., & Ishibashi, M. (2017). Germacranolides from Enhydra fluctuans with TRAIL-resistance abrogating activity. Natural product communications, 12(8), 1169-1170.